Three in 10 (30%) Americans say they’ve spent money on items to improve their mood in the past 12 months. This page includes information about these cards, currently unavailable on NerdWallet. The ...

Cell and gene therapy (CGT) development relies on speed, yet scientific complexity and operational bottlenecks can delay the moment that matters most: access to meaningful data. In today's high-cost, ...

Cell and gene therapy (CGT) has evolved from a niche research pursuit into a central force in biopharmaceutical innovation. By engineering living cells and genetic material to repair or replace faulty ...

Voyager Therapeutics, Inc. has announced that it will present eight oral and poster presentations at the American Society of Gene & Cell Therapy's upcoming annual meeting, focusing on its innovative ...

Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising clinical activity with ...

Ocugen, Inc. (OCGN) has two upcoming data readouts expected in 2024, both of which could drive shareholder value higher. This would be regarding the use of OCU-410 and OCU-410ST, which are being ...

The clinical journey for uniQure’s Huntington’s disease gene therapy got off to a bumpy start, but now the company says the latest interim data shows a slowing of disease progression. The latest ...